Strs Ohio Sells 1,300 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Strs Ohio lowered its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 5.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,300 shares of the company’s stock after selling 1,300 shares during the period. Strs Ohio’s holdings in EyePoint Pharmaceuticals were worth $538,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. FNY Investment Advisers LLC bought a new stake in EyePoint Pharmaceuticals during the fourth quarter worth about $27,000. China Universal Asset Management Co. Ltd. bought a new stake in EyePoint Pharmaceuticals during the fourth quarter worth about $94,000. Toth Financial Advisory Corp boosted its stake in EyePoint Pharmaceuticals by 42.9% during the fourth quarter. Toth Financial Advisory Corp now owns 5,000 shares of the company’s stock worth $116,000 after acquiring an additional 1,500 shares in the last quarter. Sherbrooke Park Advisers LLC bought a new position in shares of EyePoint Pharmaceuticals in the third quarter worth approximately $101,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of EyePoint Pharmaceuticals in the third quarter worth approximately $117,000. Institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Trading Up 3.7 %

Shares of EYPT stock opened at $16.75 on Friday. EyePoint Pharmaceuticals, Inc. has a 12 month low of $5.67 and a 12 month high of $30.99. The stock has a market cap of $834.65 million, a P/E ratio of -9.15 and a beta of 1.64. The company has a 50 day simple moving average of $22.45 and a two-hundred day simple moving average of $18.70.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Thursday, March 7th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.27. EyePoint Pharmaceuticals had a negative net margin of 153.84% and a negative return on equity of 61.48%. The business had revenue of $14.03 million during the quarter, compared to analysts’ expectations of $8.71 million. During the same period in the prior year, the company earned ($0.61) earnings per share. As a group, equities analysts forecast that EyePoint Pharmaceuticals, Inc. will post -1.73 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on EYPT. HC Wainwright dropped their target price on shares of EyePoint Pharmaceuticals from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, January 16th. Mizuho boosted their price objective on shares of EyePoint Pharmaceuticals from $30.00 to $39.00 and gave the company a “buy” rating in a report on Friday, February 16th. JPMorgan Chase & Co. initiated coverage on shares of EyePoint Pharmaceuticals in a report on Monday, January 22nd. They set an “overweight” rating and a $35.00 price objective for the company. Finally, Capital One Financial reissued an “overweight” rating on shares of EyePoint Pharmaceuticals in a report on Friday, February 16th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $34.00.

Insider Buying and Selling at EyePoint Pharmaceuticals

In other EyePoint Pharmaceuticals news, major shareholder Cormorant Asset Management, Lp bought 581,765 shares of EyePoint Pharmaceuticals stock in a transaction on Thursday, April 18th. The stock was acquired at an average cost of $18.03 per share, with a total value of $10,489,222.95. Following the completion of the acquisition, the insider now owns 7,475,000 shares in the company, valued at $134,774,250. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 13.05% of the stock is owned by corporate insiders.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.